A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist

Similar documents
Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.

Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to friendly IVF?

- Meta. : (rfsh); (ufsh); (IVF); : R711.6 : A : X(2015) : hmg( FSH LH) [ufsh, (ufsh-p) (ufsh-hp)] (rfsh) [1] 80, rfsh, 90, :

The Comparison of Clinical Outcomes between GnRH Agonist Long Protocol and GnRH Antagonist Short Protocol in Oocyte Donation Cycles

Comparison of follitropin-b administered by a pen device with conventional syringe in an ART programme a retrospective study

EHY Ng, WSB Yeung, PC Ho. Introduction

Key words: HCG versus GnRH agonist/ivf-gnrh antagonist cycles/ongoing pregnancy rates/oocyte maturation/rct

John Wilcox, M.D., a,e Daniel Potter, M.D., b,e Marva Moore, Ph.D., c Lee Ferrande, M.S., c and Eduardo Kelly, M.D., M.B.A. d

Cessation of gonadotropin-releasing hormone antagonist on triggering day in flexible multipledose protocol: A randomized controlled study

Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment

Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles

The use of GnRH antagonists in ovarian stimulation

Asimina Tavaniotou 1, Carola Albano 1, Johan Smitz 1 and Paul Devroey 1,2

Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles

Abstract. Introduction. RBMOnline - Vol 7. No Reproductive BioMedicine Online; on web 16 July 2003

Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.

The ganirelix dose-finding study group*

Luteal phase rescue after GnRHa triggering Progesterone and Estradiol

Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists

IVF (,, ) : (HP-hMG) - (IVF- ET) : GnRH, HP-hMG (HP-hMG )57, (rfsh )140, (Gn)

Modified Natural Cycle Using GnRH Antagonist Can Be an Optional Treatment in Poor Responders Undergoing IVF

Dipartimento di Neuroscienze, Scienze Riproduttive ed Odontostomatologiche. Tecniche di sincronizzazione ovocitaria. La sincronizzazione follicolare

Principles of Ovarian Stimulation

GnRH antagonist multiple dose protocol with oral contraceptive pill pretreatment in poor responders undergoing IVF/ICSI

Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?

Cessation of Gonadotropin-Releasing Hormone Antagonist on Triggering Day: An Alternative Method for Flexible Multiple-Dose Protocol

Premature progesterone elevation impairs implantation and live birth rates in GnRH-agonist IVF/ICSI cycles

Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M

Cigna Drug and Biologic Coverage Policy

Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation

IVF Unit, Department of Obstetrics and Gynecology, Rambam Medical Center, Haifa, Israel

A prospective randomised study comparing a GnRH-antagonist versus a GnRH-agonist short protocol for ovarian stimulation in patients referred for IVF

INTRODUCTION. Kang Woo Cheon, Sang Jin Song, Bum Chae Choi, Seung Chul Lee*, Hong Bok Lee*, Seung Youn Yu*, and Keun Jai Yoo

Recombinant FSH versus highly purified FSH in intrauterine insemination: systematic review and metaanalysis

Introduction SUMMARY. Yao-Yuan Hsieh 1, Chi-Chen Chang 1, Horng-Der Tsai 2 *

I. ART PROCEDURES. A. In Vitro Fertilization (IVF)

Comparison of serum and follicular fluid hormone levels with recombinant and urinary human chorionic gonadotropin during in vitro fertilization

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010

(BMI)=18.0~24.9 kg/m 2 ;

The serum estradiol/oocyte ratio in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins

Articles Impact of urinary FSH price: a cost-effectiveness analysis of recombinant and urinary FSH in assisted reproduction techniques in the USA

a Center of Endocrinology and Reproductive Medicine; and b Bioroma, Rome, Italy

Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF

A Tale of Three Hormones: hcg, Progesterone and AMH

Vanessa N. Weitzman, M.D., Lawrence Engmann, M.D., Andrea DiLuigi, M.D., Donald Maier, M.D., John Nulsen, M.D., and Claudio Benadiva, M.D.

Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *

STIMULATION AND OVULATION TRIGGERING

Predictive factors of successful pregnancy after assisted reproductive technology in women aged 40 years and older

Review Recombinant human follicle-stimulating hormone : a scientific step to clinical improvement

Late follicular progesterone to estradiol ratio is not influenced by protocols or gonadotropins used

ORIGINAL ARTICLE Early pregnancy

Interpreting follicular Progesterone: Late follicular Progesterone to Estradiol ratio is not influenced by protocols or gonadotropins used

Prospective study of short and ultrashort regimens of gonadotropinreleasing hormone agonist in an in vitro fertilization program

Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.

OVULATION INDUCTION. Ori Nevo, M.D., a Talia Eldar-Geva, M.D., Ph.D., b Shahar Kol, M.D., a and Joseph Itskovitz-Eldor, M.D., D.Sc.

Minimal stimulation using recombinant follicle-stimulating hormone and a gonadotropin-releasing hormone antagonist in women of advanced age

Follitropin- versus human menopausal gonadotropin in an in vitro fertilization program

Highly purified hmg versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists a randomized study

Liyan Duan 1, Shihua Bao 1, Kunming Li 1, Xiaoming Teng 1, Ling Hong 1 and Xiaoyu Zhao 2. Abstract. Introduction

Progesterone and clinical outcomes

E.G. Papanikolaou 1,2,3, *, G. Pados 1,3, G. Grimbizis 1,3, E. Bili 1,3, L. Kyriazi 3, N.P. Polyzos 4,P.Humaidan 5,H.Tournaye 4,andB.

Herjan Coelingh Bennink, M.D.:j: Andre Van Steirteghem, M.D., Ph.D.* Paul Devroey, M.D., Ph.D.*

The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (4), Page

A comparative study between agonist and antagonist protocol for ovarian stimulation in art cycles at a rural set up in South Gujarat

Drug Therapy Guidelines

Drug Therapy Guidelines

Articles Use of recombinant LH in a group of unselected IVF patients

* Puregon (recombinant FSH, Org 32489), NV Organon, Oss,

Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients

AOGS COMMENTARY SHAHAR KOL 1, ROY HOMBURG 2,3, BIRGIT ALSBJERG 4 & PETER HUMAIDAN 5. Abstract

Endometrial advancement after triggering with recombinant or urinary HCG: a randomized controlled pilot study

Clinical profiling of recombinant follicle stimulating hormone (rfsh; Puregon): relationship between serum FSH and efficacy

The effect of luteal phase progesterone supplementation on natural frozen-thawed embryo transfer cycles

Article Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study

Pituitary down-regulation in IVF/ICSI: consequences for treatment regimens Mochtar, M.H.

Hospital, No. 95, Wen Chang Road, Shih Lin District, Taipei 111, Taiwan.

Hana Park, Chung-Hoon Kim, Eun-Young Kim, Jei-Won Moon, Sung-Hoon Kim, Hee-Dong Chae, Byung-Moon Kang

In a flexible antagonist protocol, earlier, criteria-based initiation of GnRH antagonist is associated with increased pregnancy rates in IVF

Effect of highly purified urinary folliclestimulating. embryo quality

Evaluation of pretreatment with Cetrotide in an antagonist protocol for patients with PCOS undergoing IVF/ICSI cycles: a randomized clinical trial

Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol

International Journal of Reproductive Medicine & Gynecology

The emergence of Personalized Medicine protocols for IVF.

GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study

Does ovulation triggering influence the risk for ovarian hyperstimulation syndrome?

Hum. Reprod. Advance Access published March 9, 2010

Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction

PRODUCT INFORMATION. Pharmacotherapeutic group: anti-gonadotrophin releasing hormone; ATC code: H01CC01.

Ovarian response in three consecutive in vitro fertilization cycles

Duration of progesterone-in-oil support after in vitro fertilization and embryo transfer: a randomized, controlled trial

2 2nd Department of Anesthesiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece;

Judith A.F.Huirne, Andre C.D.van Loenen, Roel Schats, Joseph McDonnell, Peter G.A.Hompes, Joop Schoemaker, Roy Homburg and Cornelis B.

Elonva (corifollitropin alfa): A simplified, patientfocused

Journal of Experimental & Clinical Assisted Reproduction 2007, 4:1

Iranian Journal of Reproductive Medicine Vol. 2. No.1 pp 29-33, 2004


Rafael A. Cabrera, M.D., Laurel Stadtmauer, M.D., Ph.D., Jacob F. Mayer, Ph.D., William E. Gibbons, M.D., and Sergio Oehninger, M.D., Ph.D.

Assisted Reproduction Unit, American Hospital of Istanbul, Guzelbahce Sokak No. 20, Nisantasi, Istanbul 34365, Turkey

Transcription:

1 *, ** * * * ** A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist Yoon Sung Nam, Nam Keun Kim*, Eun Kyung Kim**, Hyung Min Chung** and Kwang Yul Cha Department of Obstetrics and Gynecology, Department of Genetics,* Department of Embryology,** College of Medicine, Pocheon CHA University, Pocheon, Korea Objective : To report the pregnancy which was made by in vitro fertilization using recombinant follicle stimulating hormone and gonadotropin releasing hormone antagonist Material and Method : Case report Results : Six oocytes were retrieved and all were fertilized by intracytoplasmic sperm injection Six embryos were transferred and the pregnancy was confirmed Conclusions : It is envisaged that the availability of recombinant gonadotropins and gonadotropin releasing hormone antagonists will ultimately lead to shorter, cheaper and safer reduced dosages treatments, using Key Words : Recombinant follicle stimulating hormone, 1

Gonadotropin releasing hormone antagonist 1980 1990 (gonadotropin releasing hormone : GnRH) (antagonist),, (agonist) Cetrorelix 3 mg 6 17 29 3 2

12 162cm, 51kg, 120 / 80 mmhg, 365 C, 80 / : 07 x 10 6 /ml, : 42%, : 4% 11 11 6 3 3 Gonal F 225 IU 5 ( 7 ) Cetrotide 025 mg hcg 4 8 10 318 miu/ml, 610 miu/ml 097 ng/ml, 190 ng/ml 6 6 12 hcg 4877 miu/ml (recombinanat follicle stimulating hormone) (urinary follicle stimulating hormone) 1-2 3

3 (basic isohormone),, 100 (bioactivity) 4 5 6 7-8 9 (agonist) (downregulation) 4

10 Gonal F Puregon,, 11 (antagonist) cetrorelix ganirelix 12-13 6 ( 7 ) hcg 14-15 cetrorelix ganirelix 025 mg 7 8 cetrorelix 3 mg 3 11 12 cetrorelix 025 mg 16 17 1 2, (granulosa cell),,, ganirelix 18 5

,, (follicular synchrony),,, hcg hcg 19 20 1 Out HJ, Mannerts BMJL, Driessen SGAJ, Coeling Bennick HJT 6

A prospective, randomised, assessor blind, multicenter study comparing recombinant and urinary follicle stimulating hormone(puregon vs Metrodin) in in vitro fertilization Hum Reprod 1995 ; 10 : 2534 40 2 Devroy P, Tournaye H, Van Steirteghem A, Hendrix P, Out HJ The use of a 100 IU starting dose recombinant follicle stimulating hormone(puregon) in in vitro fertilization Hum Reprod 1998 ; 13 : 565 6 3 De Placido G, Alviggi C, Mollo A, Strina I, Varricchio MT, Molis M Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone Hum Reprod 2000 ; 1 : 17 20 4 Out HJ, Mannerts BMJL, Driessen SGAJ, Coeling Bennick HJT Recombinant follicle stimulating hormone(rfsh ; Puregon) in assisted reproduction : more oocytes, more pregnancies Results from five comparative studies Hum Reprod Update 1996 ; 2 : 162 71 5 Recombinant Human FSH Study Group Clinical assessment of recombinant follicle stimulating hormone in stimulating ovarian follicular development before in vitro fertilization Fertil Steril 1995 ; 63 : 77 86 6 Bergh C, Howels CM, Borg K, Hamberger L, Josefsson B, Nilsson L, et al Recombinant follicle stimulating hormone(rfsh ; Gonal F) : results of a randomised comparative study in women undergoing assisted reproductive technique Hum Reprod 1997 ; 12 : 2133 9 7 Vilska S, Tiitinen A, Hyden Granskog C, Hovatta O Elective transfer of one embryo results in acceptable pregnancy rate and eliminates the risk of multiple birth Hum Reprod 1999 ; 14 : 2391 4 8 Moilanen J, Tulppala M, Reima I Fertilization, embryo quality and cryosurvival in IVF and ICSI cycles J Assist Reprod Genet 1999 ; 16 : 17 23 9 Daya S, Gunby J, Hughes EG, Collins JA, Sagle MA Follicle stimulating hormone versus human menopausal gonadotropin for in vitro fertilization : a meta analysis Fertil 7

Steril 1995 ; 64 : 347 54 10 Loumaye E, Martineau I, Piazzi A Clinical assessment of human gonadotrophins produced by recombinant DNA technology Hum Reprod 1996 ; 11 : 95 107 11 Harlin J, Csemiczky G, Wrambsy H, Fried G Recombinant follicle stimulating hormone in in vitro fertilization treatment : clinical experience with follitropin alpha and follitropin beta Hum Reprod 2000 ; 15 : 239 44 12 Albano C, Felberbaum RE, Smitz J Ovarian stimulation with HMG : results of a prospective randomized phase III European study comparing the LHRH antagonist cetrorelix and the LHRH agonist buserelin European Cetrorelix Study Group Hum Reprod 2000 ; 15 : 526 31 13 Olivennes F, Belaisch Allart J, Emperaire JC Prospective, randomized, controlled study of in vitro fertilization embryo transfer with a single dose of a LHRH antagonist(cetrorelix) or a depot formula of an LHRH agonist(triptorelin) Fertil Steril 2000 ; 73 : 314 20 14 Diedrich K, Diedrich C, Santos E Suppression of the endogenous luteinizing hormone surge by the gonadotrophin releasing hormone antagonist Cetrorelix during ovarian stimulation Hum Reprod 1994 ; 9 : 788 91 15 Albano C, Smitz J, Camus M Comparison of different doses of gonadotropin releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation Fertil Steril 1997 ; 67 : 917 22 16 Olivennes F, Fanchin R, Bouchard P Scheduled administration of a gonadotropin releasing hormone antagonist(cetrorelix) on day 8 of in vitro fertilization cycles : a pilot study Hum Reprod 1995 ; 10 : 1382 6 17 Albano C, Grimbizis G, Smitz J The luteal phase of nonsupplimented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin releasing hormone antagonist Cetrorelix Fertil Steril 1998 ; 70 : 357 9 18 Hernandez ER Embryo implantation : the Rubicon for GnRH 8

antagonists Hum Reprod 2000 ; 15 : 1211 6 19 Felberbaum RE, Reissmann T, Kupker W Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists(cetrorelix) in women with tubal infertility Eur J Obstet Gynecol Reprod Biol 1995 ; 61 : 151 5 20 Olivennes F, Fanchin R, Bouchard P Triggering of ovulation by a gonadotropin releasing hormone(gnrh) antagonist in patients pretreated with a GnRH antagonist Fertil Steril 1996 ; 66 : 151 3 9